REPLIGEN CORP Inventory, Finished Goods, Net of Reserves
REPLIGEN CORP (RGEN) had Inventory, Finished Goods, Net of Reserves of $61.92 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-07-29
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $61.92M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $57.15M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $55.03M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $72.17M.
| Period end | Inventory, Finished Goods, Net of Reserves | Inventory, Finished Goods, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $61.92M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $57.15M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $55.03M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $72.17M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $71.00M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $63.82M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $56.21M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $68.83M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $73.79M 10-Q/A · filed 2024-11-18 | |
| 2024-03-31 | $74.18M 10-Q/A · filed 2024-11-18 | |
| 2023-12-31 | $74.23M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $76.85M 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $88.06M 10-Q/A · filed 2024-11-18 | |
| 2023-03-31 | $88.03M 10-Q/A · filed 2024-11-18 | |
| 2022-12-31 | $82.66M 10-Q/A · filed 2024-11-18 | |
| 2022-09-30 | $88.20M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $90.32M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $68.19M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $53.05M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $43.15M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $40.44M 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $34.42M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $38.20M 10-K · filed 2022-02-17 | |
| 2020-09-30 | $30.14M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $23.86M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $19.80M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $17.14M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $16.94M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $13.04M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $12.58M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $12.14M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $11.66M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $12.61M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $14.47M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $12.57M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $12.79M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $7.09M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $5.77M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $6.95M 10-K · filed 2018-02-22 | |
| 2016-09-30 | $6.77M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $6.21M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $5.36M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $5.74M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $4.12M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $3.83M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $4.33M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $4.75M 10-K · filed 2016-02-25 | $4.75M 10-K · filed 2015-03-17 |
| 2014-09-30 | $4.47M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $4.60M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $4.18M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $2.96M 10-K · filed 2015-03-17 | |
| 2013-09-30 | $2.12M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $2.33M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $2.97M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $2.97M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $1.59M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $2.26M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $3.86M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |